612
Participants
Start Date
December 8, 2020
Primary Completion Date
March 25, 2027
Study Completion Date
November 30, 2027
REGN5668
Administer per the protocol
Cemiplimab
Administer per the protocol
Ubamatamab
Administer per the protocol
Sarilumab
Administer per the protocol
Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]
Administer per the protocol
RECRUITING
Universitair Ziekenhuis Leuven, Leuven
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Centre Francois Baclesse (CFB), Caen
RECRUITING
Hospital Clinico Universitario Santiago de Compostela, Santiago de Compostela
RECRUITING
Institut Catala dOncologia Girona, Girona
RECRUITING
Perelman School of Medicine at the University of Pennsylvania, Philadelphia
RECRUITING
Centre Georges Francois Leclerc, Dijon
RECRUITING
Ciudad Universitaria, Madrid
RECRUITING
Hospital Universitario Fundacion Jimenez, Madrid
RECRUITING
Hospital Universitario 12 de Octubre Universidad Complutense de Madrid UCM, Madrid
RECRUITING
Institut Bergonie, Bordeaux
COMPLETED
H. Lee Moffitt Cancer Center, Tampa
RECRUITING
The Ohio State University Wexner Medical Center, Columbus
RECRUITING
Karmanos Cancer Institute, Detroit
RECRUITING
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
RECRUITING
University of Chicago Medical Center, Chicago
RECRUITING
Hopital Lyon Sud, Pierre-Bénite
RECRUITING
The City of Hope Orange County Lennar Foundation Cancer Center, Irvine
RECRUITING
Chao Family Comprehensive Cancer Center, Orange
RECRUITING
Institut Gustave Roussy, Villejuif
RECRUITING
Seattle Cancer Care Alliance at South Lake Union - G3630, Seattle
RECRUITING
City of Hope Comprehensive Cancer Center, Duarte
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Dana Farber Cancer Institute Brookline Avenue, Boston
Regeneron Pharmaceuticals
INDUSTRY